Tokyo, March 6, 2018
Noile-Immune Biotech, Inc., a biotechnology company focusing on the development of CAR-T therapy, today announced the publication in the Nature Biotechnology of novel CAR-T platform technology for the treatment of solid tumors.
Our research collaborator, Dr. Koji Tamada's research group in Yamaguchi University Graduate School of Medicine, Department of Immunology, reports their research result of "Prime-CAR-T" technology in the Nature Biotechnology.
Detailed information is below.
Prime CAR-T technology: Proliferation-inducing and migration-enhancing technology. Prime-CAR-T utilize cytokine and chemokine and has been expected it exert more effective for cancer therapy in solid tumor.
About Noile-Immune Biotech Inc
Noile-Immune Biotech, Inc., based in Tokyo, Japan, was founded in 2015 as a biotechnology company focusing on the development of innovative cancer immunotherapy. The Prime CAR-T technology was developed by Professor Koji Tamada. Noile-Immune will accelerate execution of clinical trials through its partnerships with the National Cancer Center Japan and Yamaguchi University.
Additional information about Noile-Immune is available through its website,